MA54638A - Formes cristallines d'un stimulateur de sgc - Google Patents
Formes cristallines d'un stimulateur de sgcInfo
- Publication number
- MA54638A MA54638A MA054638A MA54638A MA54638A MA 54638 A MA54638 A MA 54638A MA 054638 A MA054638 A MA 054638A MA 54638 A MA54638 A MA 54638A MA 54638 A MA54638 A MA 54638A
- Authority
- MA
- Morocco
- Prior art keywords
- cgm
- stimulator
- crystalline forms
- crystalline
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639846P | 2018-03-07 | 2018-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54638A true MA54638A (fr) | 2021-11-10 |
Family
ID=65818696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054638A MA54638A (fr) | 2018-03-07 | 2019-03-07 | Formes cristallines d'un stimulateur de sgc |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11466015B2 (https=) |
| EP (1) | EP3762389B1 (https=) |
| JP (1) | JP7423539B2 (https=) |
| KR (1) | KR102782810B1 (https=) |
| CN (1) | CN111836812A (https=) |
| AU (1) | AU2019231724B2 (https=) |
| BR (1) | BR112020018212A2 (https=) |
| CA (1) | CA3092683A1 (https=) |
| CL (5) | CL2020002284A1 (https=) |
| CO (1) | CO2020012493A2 (https=) |
| CR (1) | CR20200458A (https=) |
| EA (1) | EA202092109A1 (https=) |
| ES (1) | ES2980256T3 (https=) |
| IL (1) | IL276853B1 (https=) |
| MA (1) | MA54638A (https=) |
| MX (5) | MX2023004858A (https=) |
| PE (1) | PE20210124A1 (https=) |
| PH (1) | PH12020551394A1 (https=) |
| SG (1) | SG11202008641WA (https=) |
| TW (1) | TWI823903B (https=) |
| WO (1) | WO2019173551A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019231724B2 (en) | 2018-03-07 | 2024-06-27 | Tisento Therapeutics Inc. | Crystalline forms of an sGC stimulator |
| KR20210031931A (ko) * | 2018-07-11 | 2021-03-23 | 사이클리온 테라퓨틱스, 인크. | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 |
| US20230130739A1 (en) * | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| EP4640676A1 (en) * | 2022-12-21 | 2025-10-29 | Sunshine Lake Pharma Co., Ltd. | Crystal form of fluorine-substituted indazole compound and use thereof |
| AU2023412238A1 (en) * | 2022-12-21 | 2025-07-03 | Sunshine Lake Pharma Co., Ltd. | Crystal form of fluorine-substituted indazole compound and use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| CN1332943C (zh) | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| KR20100059952A (ko) | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
| WO2009094242A1 (en) | 2008-01-24 | 2009-07-30 | Merck & Co., Inc. | Angiotensin ii receptor antagonists |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| AR088020A1 (es) | 2010-06-30 | 2014-05-07 | Ironwood Pharmaceuticals Inc | Compuestos heterociclicos como estimuladores de sgc |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2637659B1 (en) | 2010-11-09 | 2016-05-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| CA2891976C (en) | 2012-11-30 | 2020-07-21 | Astellas Pharma Inc. | Imidazopyridine compounds |
| US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
| CN104327107A (zh) | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| EP3194386A2 (en) | 2014-09-17 | 2017-07-26 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| CN107257796A (zh) * | 2014-12-02 | 2017-10-17 | 拜耳医药股份有限公司 | 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途 |
| CR20220309A (es) * | 2016-09-02 | 2022-09-16 | Cyclerion Therapeutics Inc | Estimuladores de sgc |
| AU2019231724B2 (en) | 2018-03-07 | 2024-06-27 | Tisento Therapeutics Inc. | Crystalline forms of an sGC stimulator |
-
2019
- 2019-03-07 AU AU2019231724A patent/AU2019231724B2/en active Active
- 2019-03-07 SG SG11202008641WA patent/SG11202008641WA/en unknown
- 2019-03-07 MA MA054638A patent/MA54638A/fr unknown
- 2019-03-07 PE PE2020001347A patent/PE20210124A1/es unknown
- 2019-03-07 MX MX2023004858A patent/MX2023004858A/es unknown
- 2019-03-07 CN CN201980017657.XA patent/CN111836812A/zh active Pending
- 2019-03-07 EA EA202092109A patent/EA202092109A1/ru unknown
- 2019-03-07 ES ES19712427T patent/ES2980256T3/es active Active
- 2019-03-07 JP JP2020546378A patent/JP7423539B2/ja active Active
- 2019-03-07 MX MX2023004857A patent/MX2023004857A/es unknown
- 2019-03-07 US US16/976,430 patent/US11466015B2/en active Active
- 2019-03-07 MX MX2020009183A patent/MX2020009183A/es unknown
- 2019-03-07 EP EP19712427.4A patent/EP3762389B1/en active Active
- 2019-03-07 CA CA3092683A patent/CA3092683A1/en active Pending
- 2019-03-07 MX MX2023004855A patent/MX2023004855A/es unknown
- 2019-03-07 TW TW108107664A patent/TWI823903B/zh active
- 2019-03-07 CR CR20200458A patent/CR20200458A/es unknown
- 2019-03-07 MX MX2023004856A patent/MX2023004856A/es unknown
- 2019-03-07 BR BR112020018212-5A patent/BR112020018212A2/pt unknown
- 2019-03-07 WO PCT/US2019/021080 patent/WO2019173551A1/en not_active Ceased
- 2019-03-07 KR KR1020207028170A patent/KR102782810B1/ko active Active
-
2020
- 2020-08-20 IL IL276853A patent/IL276853B1/en unknown
- 2020-09-03 CL CL2020002284A patent/CL2020002284A1/es unknown
- 2020-09-05 PH PH12020551394A patent/PH12020551394A1/en unknown
- 2020-10-06 CO CONC2020/0012493A patent/CO2020012493A2/es unknown
-
2021
- 2021-02-04 CL CL2021000301A patent/CL2021000301A1/es unknown
- 2021-12-28 CL CL2021003531A patent/CL2021003531A1/es unknown
- 2021-12-28 CL CL2021003530A patent/CL2021003530A1/es unknown
- 2021-12-28 CL CL2021003536A patent/CL2021003536A1/es unknown
-
2022
- 2022-09-28 US US17/954,713 patent/US12122782B2/en active Active
-
2024
- 2024-10-21 US US18/921,161 patent/US20250115611A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| EP3472168A4 (en) | CRYSTALLINE FORMS OF A TRIAZOLOPYRIMIDINE COMPOUND | |
| EP3924352A4 (en) | CRYSTALLINE FORMS OF AN RSK INHIBITOR | |
| EP3853771A4 (en) | DIGITAL WATERMARKS FOR MACHINE LEARNING MODELS | |
| IL280001A (en) | Device for facilitating the formation of new bone tissue | |
| EP3807279A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| EP3841465A4 (en) | FILTERED BRANCH PREDICTION STRUCTURES OF A PROCESSOR | |
| EP3638875A4 (en) | GENERATING DRILLING PATHS USING A DRILLING MODEL | |
| EP3852631A4 (en) | An imaging method | |
| DK3685809T3 (da) | Stimuleringsanordning til en mands penis | |
| IL289453A (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| IL288348A (en) | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof | |
| EP3337485A4 (en) | CRYSTALLINE FORMS OF IBRUTINIB | |
| MA54689A (fr) | Formes cristallines de 1-(1,2-diméthylpropyl)-n-éthyl-5-méthyl-n-pyridazin-4-yl-pyrazole-4-carboxamide | |
| EP3592377A4 (en) | DOSAGE FORMS OF TISSUE KALLIKREIN 1 | |
| EP3829551A4 (en) | CRYSTALLINE EPINEPHRIN MALONATE SALT | |
| HUE061296T2 (hu) | Meta-diamid vegyületek gerinctelen kártevõk irtására | |
| EP3897660A4 (en) | NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND | |
| EP3923721A4 (en) | IMPROVED ENDOSCOPIC DISINFECTANT | |
| EP3672972A4 (en) | SALT OF A COMPOUND AND CRYSTALLINE FORMS OF IT | |
| IL286007A (en) | Preparation method for revitalizing a biocompatible tissue | |
| EP3819297A4 (en) | CRYSTAL FORMS OF THE THIAZOLE COMPOUND AND APPLICATIONS THEREOF | |
| IL278054A (en) | The crystalline forms of a compound |